Fear of meningococcal 'superstrain' can be dominant.

Scientists say that if the price is set by overseas trends, the "deformation" of meningococcal disease that killed six lives this year will be dominant in New Zealand.

The Institute of Environmental Science (ESR) has started reporting on WW Meningococcal Infections (MenW), which have increased from five in 2016 to 24 this year.

Emergency and emergency rooms should be alert for possible symptoms.

A fatal example is Whangarei (age 7), Alexander Albert. He wants vaccination and awareness programs nationwide. Kerry Kerry (16 year old Dion Hodder) is a Motapu Island youth camp.

Meningococcal disease is a bacterial infection that causes meningitis (infection of the brain covering membrane) and sepsis, or poisoning.

Meningococcal B (MenB) has long been a dominant variant in New Zealand, but two-thirds of the disease has raised concerns about MenW's injury.

The proportion of MenW fell from 67% in 2017 to 49%, while the proportion of MenW rose from 11% to 28%.

Dr. ESR Public Health Doctor. Jill Sherwood said the increase in the past two years was "significantly higher" than the annual average of 2012-2015 when only 2.5 were reported.

I was especially worried because it was more difficult to diagnose, more toxic, and more likely to have a higher mortality rate.

Affected more than 40% of the age group associated with adults over 40 years of age.

New Zealand is likely to follow trends in other countries, such as Australia, where MenW became the dominant country in 2016.

"The number of MenW cases in New Zealand is still relatively low, but there is an increasing trend in notifications and a recent change in a sequential pattern similar to the UK, Australia and Canada."

When MenW passed or MenB could not predict, the number of cases was small, Sherwood said.

ESR monitored patterns of meningococcal disease by looking for patterns based on basic demographics such as age, gender, race, location, lifestyle, and onset date.

"For meningococcal disease, we also look at group and strain types and examine how many cases of the same strains and groups have not been in close contact with one another within the last three months."

In the early 2000s, the government implemented a nationwide vaccination program following the outbreak of menB, but has since been excluded from the vaccination schedule.

However, the government is now considering ways to openly support the vaccination against new meningococcal disease, including MenW.

Nikki Turner, an associate professor at the Immunization Advisory Center, said that New Zealand vaccines were available for some high-risk groups that could be purchased, but did not meet the national schedule.

"We know that our authorities have an intention to introduce this vaccine in New Zealand, and we continue to do so," Turner said.

"It's a bit complicated and many factors need to be weighed."

Turner pointed out that although vaccines are effective, they do not protect them for the rest of their lives.

"Diseases occur primarily in infants, young children, and adolescents, and organisms are usually carried in the throat of a teenager, but not exclusively."

"Schedules focusing on these two ages will be most effective because we already have a lot of vaccines on our infant's schedule so we can add them elsewhere but it's not that simple.

"Adolescents also seem to need a dose and are currently on a vaccination schedule at the middle school age, but not high school students who are suffering from older elderly people before the vaccine is in effect."

Another complicated problem was the role of "herd immunity". The immune system has helped to protect a small number of vulnerable people.

"If we carry out campaigns for all youths, we will be able to prevent more diseases by reducing the transport of creatures in people's necks before vaccination," he said.

New Zealand said it was not the country that best practices disease control.

"I believe there is a definite role for the vaccine here, but sadly they will not be magic bullets."

By number

28%

The W group rate of cases of meningococcal disease this year, which was 11% last year – six of them are fatal.

49% The percentage of the dominant B group this year was down from 67 percent last year.

15%: Potential rates of fatal MenW cases.

40%: More than 4 out of 10 cases include patients over 40 years old.